The first generic version of the popular Advair asthma inhaler has been approved by U.S. regulators.
The Food and Drug Administration on Wednesday approved Mylan’s version in three strengths for ages 4 and up.
The inhalers are used twice daily to keep airways open and prevent flare-ups of wheezing, shortness of breath and other symptoms of asthma or chronic obstructive pulmonary disease. About 42 million Americans have those conditions.
The device contains two medicines, inhaled in a precise mixture. That complexity has stymied a couple of other companies developing generic versions of GlaxoSmithKline’s Advair Diskus inhaler, which costs about $400 a month.
Generics generally are cheaper. Mylan didn’t immediately respond to queries about when its inhaler, called Wixela Inhub, will be available or what the price will be.
Sourse: abcnews.go.com
0.00 (0%) 0 votes
MOSCOW (Sputnik) - The Coalition for the Restoration of Democracy (CORED), which unites 18 opposition parties in Guinea, said on…
The news of an interplanetary scale comes after NASA believed it had captured its first sample with Perseverance last month,…
MOSCOW (Sputnik) - The last pipe of the second string of Nord Stream 2 has been welded, and after a…
LONDON (Sputnik) – The UK government on Monday condemned the military coup against the president of Guinea, Alpha Conde, and…